iShares MSCI Singapore ETF vs Relay Therapeutics Inc. Common Stock — how do they compare? iShares MSCI Singapore ETF trades at $31.6 (market cap $1.49B), while Relay Therapeutics Inc. Common Stock trades at $17.88 (market cap $3.82B). The key difference: Relay Therapeutics Inc. Common Stock is far larger — about 2.6× iShares MSCI Singapore ETF's market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares MSCI Singapore ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Singapore ETF for 45 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| EWS | RLAY | |
|---|---|---|
Market Cap | $1.49B | $3.82B |
Volume | 2,142,305 | 4,332,079 |
Sector | Broad Market / Factor | Health |
52-Week High | $34.57 | $20.75 |
52-Week Low | $26.71 | $6.03 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | — | $2.93B |
Signals from Pluang's Aura AI — not financial advice
EWS (iShares MSCI Singapore ETF) trades at $31.60, down 2.71% with bearish technical signals from moving averages and oscillators. The ETF recently hit 52-week highs amid Singapore's strong economic growth and AI momentum, attracting institutional interest including Amundi's 4.8% position increase. Key support sits at $31 with resistance at $32.
Outlook remains mixed with technical weakness offset by positive fundamental drivers. Investment opportunity lies in Singapore's economic resilience and AI-driven growth, though stretched valuations and bearish momentum present near-term risks. The ETF offers exposure to Asia's outperformance versus S&P 500 but faces volatility from regional economic sensitivity.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →